Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation;Thrombopénie auto-immune associée à une réactivation virale B (séroréversion HBs) après autogreffe de moelle

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 1, 2007, Pages 97-99

  Aubourg, Alexandre ^a   D'Alteroche, Louis ^a   Senecal, Delphine ^b   Gaudy, Catherine ^b   Bacq, Yannick ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b CHU BRETONNEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; CD20 ANTIBODY; CHLORAMBUCIL; DEXAMETHASONE; DOXORUBICIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CASE REPORT; DISEASE CONTROL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MALE; RECURRENT DISEASE; SEROCONVERSION; VIRUS REPLICATION;

EID: 33846781500     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(07)89335-3     Document Type: Article

References (19)

1. Lau GKK, Leung YH, Fong DYT, Au WY, Kwong YI, Lie A, et al. High hepatitis B virus DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-30.
2. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004;5:270-5.
3. Simpson ND, Simpson PW, Ahmed AM, Nguyen MH, Garcia G, Keefe EB, et al. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. J Clin Gastroenterol 2003;37:68-71.
4. Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
5. Yeo W, Chan PKS, Hui P, Ho WM, Lam KC, Kwam WH, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553-61.
6. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, HO WM, et al. Comprehensive analysis of risk factors associating with hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-11.
7. Onozawa M, Hashino S, Izumiyama K, Kahata K, Chuma M, Mori A, et al. Progressive disappearance of anti-hepatitis B surfaces antigen antibody and reverse seroconversion after allogenic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005;79:616-9.
8. Romand F, Michallet M, Pichoud C, Trepo C, Zoulim F. Réactivation virale B après greffe de moelle allogénique chez un malade précédemment guéri d'une hépatite virale B. Gastroenterol Clin Biol 1999;23:770-4.
9. Cheng AL, Hsiung CA, Su IJ. Steroid-free chemotherapy decreases risk of hepatitis B virus reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320-8.
10. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004;83:769-74.
11. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Eng J Med 2001;344:68-9.
12. Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627-9.
13. Vega MI, Huerta-Yepez S, Jazirehi A, Garban H, Bonavida B. Rituximab (chimeric anti-CD 20) sensitizes B-NHL cell lines to Fasinduced apoptosis. Oncogene 2005;25:8114-27.
14. Ozaras R, Celik AD, Kisack B, Mert A, Aki H, Ozturk R, et al. Acute hepatitis B and isolated thrombocytopenia. J Clin Gastroenterol 2003;37:87-8.
15. Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TS. Preemptive use of lamivudine in breast cancer patients carrying hepatits B virus undergoing cytotoxic chemotherapy: a longitudinal follow-up. Support Care Cancer 2004;12:191-6.
16. Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC. Adefovir Dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. New Eng J Med 2005;352:310-11.
17. Enomoto M, Nishiguchi S, Seki S, Yamane T, Hino M. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma. Am J Gastroenterol 2004; 99:1619-20.
18. Hadziyannis S, Tassopoulos N, Chang TT, Heathcote J, Kitis G, Rizetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B. N Eng J Med 2005;352:2673-81.
19. Papatheodoridis GV, Hadziyannis SJ. Review article: current management of chronic hepatitis B. Aliment Pharmacol Ther 2004;19:25-37.